Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satori-01
- Development stage
- Phase 2
- Lead developer
- MyoPax
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Satori-01 is a regenerative cell therapy consisting of patient-specific muscle stem cells designed to repair the urinary sphincter muscle defect associated with Exstrophy-Epispadias Complex (EEC). This rare congenital disease causes malformation of the genital and urinary organs, impacting urinary continence, sexual, and renal function. Current standard of care involves multiple reconstructive surgeries and lifelong management with incomplete correction. Satori-01 aims to provide a more effective solution through muscle regeneration.
- Other names
- Primary Human Satellite cell-derived muscle stem cells (MyoPax)Primary human muscle stem cells (MyoPax)
Beyond the preview
Go deeper on satori-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on satori-01.